Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Anticancer Res. 2022 May;42(5):2791-2795. doi: 10.21873/anticanres.15759.
BACKGROUND/AIM: Surgical resection and chemoradiotherapy (CRT) can be performed as additional treatments for superficial esophageal cancer after endoscopic resection, but the selection criteria vary depending on the institution. We retrospectively evaluated the outcomes of patients with endoscopically resected superficial esophageal cancer treated with surgical resection and CRT at our institution.
The outcomes of 67 cases of additional treatment after endoscopic resection of superficial esophageal cancer, excluding adenocarcinoma, performed at our hospital from January 2000 to June 2017 were compared (30 cases in the surgery group and 37 cases in the CRT group).
In the surgery group, eight patients had lymph node metastasis and two had recurrence in the supraclavicular fossa lymph nodes after surgery, therefore reoperation was performed. There were no deaths from esophageal cancer, and the 5-year survival rate was 92.6%. One patient in the CRT group had a recurrence in the cervical paraoesophageal lymph node, which was resected, but no death from esophageal cancer was observed, and the 5-year survival rate was 81.0%. The 5-year survival rate was significantly better in the surgery group than in the CRT group (p=0.039). The greater number of elderly patients in the CRT group was considered to be the reason for the worse prognosis, Conclusion: Although the prognosis of esophagectomy or chemoradiotherapy (CRT) is very favorable, CRT is considered to be the preferred additional treatment after endoscopic resection of superficial esophageal cancer without lymph node metastasis from the viewpoint of organ preservation.
背景/目的：内镜切除术后，可对表浅性食管癌进行手术切除和放化疗（CRT）作为附加治疗，但选择标准因机构而异。我们回顾性评估了我院内镜切除表浅性食管癌患者接受手术切除和 CRT 治疗的结果。
我们比较了 2000 年 1 月至 2017 年 6 月我院行内镜切除表浅食管癌（不包括腺癌）后进行附加治疗的 67 例患者的结局（手术组 30 例，CRT 组 37 例）。
手术组 8 例患者术后发生淋巴结转移，2 例患者锁骨上窝淋巴结复发，因此进行了再次手术。无食管癌死亡病例，5 年生存率为 92.6%。CRT 组 1 例患者出现颈段食管旁淋巴结复发，再次切除，无食管癌死亡病例，5 年生存率为 81.0%。手术组的 5 年生存率明显优于 CRT 组（p=0.039）。CRT 组老年患者较多，被认为是预后较差的原因。
尽管手术或放化疗（CRT）的预后非常好，但从保留器官的角度考虑，对于无淋巴结转移的表浅性食管癌，CRT 被认为是内镜切除后的首选附加治疗。
